RLAY · Relay Therapeutics, Inc.
$18.12
-0.33% last session
End-of-day data · close of 2026-10-26
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-11.1
Dividend yield
0.0%
Beta
1.73
Avg volume
3M
Employees
0K
Daily Change %
-0.33%
5 Days Change
6.38%
10 Days Change
6.57%
30 Days Change
2.54%
60 Days Change
-11.62%
Month to Day Change
-1.68%
Year to Day Change
114.89%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RLAY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-20
Latest call per bank · past 12 months
JP Morgan
Overweight$31.00
+70.5% vs priceBarclays
Overweight$30.00
+65.0% vs priceGoldman Sachs
Buy$31.00
+70.5% vs priceWells Fargo
Overweight$21.00
+15.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-20 | HC Wainwright & Co. | Maintains | Buy | $28.00 → $29.00 |
| 2026-08-14 | JP Morgan | Maintains | Overweight | $28.00 → $31.00 |
| 2026-08-10 | Citizens | Maintains | Market Outperform | $21.00 → $26.00 |
| 2026-08-07 | Barclays | Maintains | Overweight | $27.00 → $30.00 |
| 2026-07-21 | Goldman Sachs | Maintains | Buy | $22.00 → $31.00 |
| 2026-07-16 | Canaccord Genuity | Initiates | Buy | $0.00 → $29.00 |
| 2026-07-08 | JP Morgan | Initiates | Overweight | $0.00 → $28.00 |
| 2026-05-26 | Guggenheim | Maintains | Buy | $22.00 → $26.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 2.7% below the 50-day MA ($18.63).
- bullish: Price vs 200-day MA: Trading 22.7% above the 200-day MA ($14.77).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.11) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($6.05) and high ($20.75).
RLAY Price Chart
Loading chart for RLAY…
Fundamentals
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.